NVAX240628P17500
- 4.98
- 0.000.00%
Novavax Newsroom
After falling to an 11-year low and consolidating for several months, should I buy or sell pfizer (PFE.US) now?
In April of this year, Pfizer's (PFE.US) stock price fell to its lowest point since January 2013. As of the closing of July 1st, the stock has risen by about 11% since then; after falling to an 11-year low, Pfizer has been in a consolidation phase for several months. So, should you sell or buy Pfizer stocks now? From a fundamental perspective, Pfizer is still trying to overcome the drag of the cooling of its COVID-19 product and pushing forward the development of non-COVID-19 drug businesses. Recently, the company announced positive results from trials of two cancer drugs, but also closed a gene therapy program, and its stock price continues to range. In a study, patients received Pfizer's Elrex
(NVAX) - Analyzing Novavax's Short Interest
Novavax's (NYSE:NVAX) short percent of float has risen 3.9% since its last report. The company recently reported that it has 39.71 million shares sold short, which is 34.36% of all regular shares that
COVID Infections Could Be Seeing a Summer Surge Based on CDC Data
Express News | Novavax Inc - Intends to Have Its Vaccine Available in Canada for Immediate Release Post-Authorization
Express News | Novavax Submits Application to Health Canada for Updated Protein-Based 2024-2025 Formula Covid-19 Vaccine
Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine
Novavax's COVID-19 vaccine would be the only protein-based option available in Canada, if authorizedNovavax's filing is aligned with NACI, U.S. FDA, EMA and WHO recommendations on vaccine compositionG
Jim Cramer Says You Should Not Buy Novavax Inc (NASDAQ:NVAX)
Where Will Novavax Be in 1 Year?
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
Express News | U.S. Cdc: Updated 2024-2025 Flu Vaccines Will All Be Trivalent and Will Protect Against an H1N1, H3N2 and a B/Victoria Lineage Virus
Express News | U.S. Cdc: Updated Covid-19 Vaccines Will Be Available From Moderna, Novavax, and Pfizer Later This Year
Express News | Novavax- Updated Version of Novavax Covid-19 Vaccine Currently Under Review by U.S. FDA for Eua to Prevent Covid-19 in Individuals Aged 12 and Older
Express News | Novavax - Intends to Provide Doses of 2024-2025 Covid-19 Vaccine at Start of Vaccination Season and Upon Eua by U.S. Food and Drug Administration
Express News | Novavax Inc - U.S. Acip Recommends Use of Authorized and Approved 2024-2025 Covid-19 Vaccines
Express News | U.S. Cdc Advisers Recommend Updated Covid-19 Vaccines for Persons Aged Six Months and Above
Novavax Insiders Sold US$593k Of Shares Suggesting Hesitancy
Novavax, Inc. (NASDAQ:NVAX) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When evaluating insider transactions, knowing whether insiders are
U.S. ACIP Recommends Use of Authorized and Approved 2024-2025 COVID-19 Vaccines
Today the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted unanimously in favor of a universal recommendation for the use of 2024-2025
Decoding Novavax's Options Activity: What's the Big Picture?
Whales with a lot of money to spend have taken a noticeably bullish stance on Novavax.Looking at options history for Novavax (NASDAQ:NVAX) we detected 10 trades.If we consider the specifics of each tr
Novavax(NVAX.US) Director Sells US$105.68K in Common Stock
$Novavax(NVAX.US)$ Director YOUNG JAMES F sold 7,500 shares of common stock on Jun 21, 2024 at an average price of $14.09 for a total value of $105.68K.Source: Announcement What is statement of change
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,300 Today
Novavax (NASDAQ:NVAX) has outperformed the market over the past 5 years by 6.35% on an annualized basis producing an average annual return of 19.29%. Currently, Novavax has a market capitalization of